Sentences with phrase «of vaccine technology»

Recombinant vaccines represent the very cutting edge of vaccine technology in both veterinary and human medicine.

Because the H10N8 and H7N9 strains are not circulating in the general population where the trials are taking place (the U.S. and Germany), Moderna is able to study the efficacy of its vaccine technology in naïve patient populations.

The HZI will provide expertise and technologies for adjuvants and the preclinical validation of vaccine technologies and candidates in murine systems.

Not exact matches

«We are honored to receive this award which underscores the unique value of our technology platform and its game changing potential to make novel vaccines for important human diseases.»

You not that «not many people think of childhood vaccines or pacemakers etc as unnatural or life extension technology,» but they are!

Today, Cuba has a hardy biotechnology industry that exports a number of important vaccines, antibody - based drugs and other biomedical technologies.

This technology could help researchers rapidly generate new peptide drugs to test on a variety of diseases, and it also raises the possibility of easily producing customized cancer vaccines for individual patients.

It's also a stark contrast to today's egg - based technology, which takes about six months to produce a mere 100 million doses, according to Alan Shaw, CEO of VaxInnate, a company at the forefront of bacteria - based vaccine production.

Poland reckons doctors will be able to use the technology to predict whether a person is likely to respond to a vaccine, or if they are at risk of side effects.

VaxInnate is testing a universal flu vaccine that would work against all strains of the disease by using a Toll - like receptor (TLR) technology platform.

To create a new dengue virus vaccine, Stefan Metz, Shaomin Tian in the laboratories of Aravinda de Silva, Chris Luft and Joe DeSimone at the University of Carolina, Chapel Hill, USA designed nanoparticles of various shapes and sizes using Particle Replication in Non-wetting Template (PRINT) technology.

«However, the promising results of this trial lay the foundations for the development of a more cost - effective, clinically - practical vaccine technology that could deliver similar outcomes for patients.

Phase II trials for that vaccine candidate are set to begin within the next two months, so it will not likely be available to combat the current swine flu outbreak, which could kill as many as 90,000 Americans and land up to 1.8 million in the hospital, according to the President's Council of Advisors on Science and Technology (PCAST).

Other scientists add that it should force governments to rethink existing vaccine technologies, which are only capable of supplying vaccine six months after a pandemic starts, and of producing enough vaccine for a small fraction of the world population.

«This is a big deal,» says Nobel laureate David Baltimore, president of the California Institute of Technology and head of a U.S. government advisory panel on AIDS vaccines.

It exports a number of vaccines, antibody - based drugs and other biomedical technologies.

Moderna is a clinical stage pioneer of messenger RNA (mRNA) therapeutics and vaccines, an entirely new drug technology that directs the body's cells to produce intracellular or secreted proteins.

Ingo Potrykus at the Swiss Federal Institute of Technology is engineering a novel strain of rice fortified with extra iron and vitamin A. Charles Arntzen, president of the Boyce Thompson Institute for Plant Research at Cornell University, is working on perhaps the most ambitious genetically engineered food of all: an edible vaccine.

of the world since it began nearly three years ago, and he suggests a way to prevent similar disputes in the future: Developed countries should provide technology transfer to help poor countries, allowing them to produce their own vaccines.

Examples include changing policies to encourage older adults to remain part of the workforce for longer (e.g., removing tax disincentives to work past retirement age), emphasising low - cost disease prevention and early detection rather than treatment (eg, reducing salt intake and increasing uptake of vaccines), making better use of technology (eg, mobile clinics for rural populations), and training health - care staff in the management of multiple chronic conditions.

5) Explore new vaccine technologies — Longer term, we need to evaluate new ways to vaccinate wild carnivores for distemper, in situations wherein use of an injectable vaccine is not feasible by hand or by dart.

Along with discussing the potential benefits — such as making seed vaccines in a day and producing biofuels — some debated whether Venter's part - artificial bacterium is a major advance or simply an extension of existing DNA technologies.

Jury member Penny Heaton, director of vaccine development at the Bill & Melinda Gates Foundation, said CureVac's RNA technology had «the potential for a large and positive impact on public health,» in a statement released by the company on 10 March.

«Now I see how vaccine technology can be used against a host of public health issues.»

In November 2012, the company also showed, along with scientists from the Friedrich Loeffler Institute, that the technology could lead to a new generation of flu vaccines.

With the completion of the first phase of the Human Genome Project in 2000, and the advent of sequencing technologies that can detect gene variations such as single nucleotide polymorphisms (SNPs), for the first time scientists have the tools in hand to find the key immune genes and genetic networks that play roles in vaccine response.

The majority of new drugs and vaccines are developed within the private sector and they are developed as commercial goods so there is a lack of a public mechanism to advance R&D of new technologies.

There are ongoing studies which focus on the discovery of molecular biomarkers of the VSV - ZEBOV vaccine in healthy individuals using omics - based technologies in combination with a systems biology approach,» says Ali Harandi.

Significantly, J&J's latest vaccine uses so - called mosaic technology to combine immune - stimulating proteins from different HIV strains, representing different types of virus from around the world, which should produce a «global» vaccine.

The winners of the prize are Maged Al - Sherbiny from Egypt, for his research on vaccines and diagnostics against hepatitis C and schistosomiasis; plant scientist Felix Dapare Dakora from Tshwane University of Technology, Pretoria, in South Africa for his work on legumes and soil bacteria; and Rossana Arroyo of the Centre for Research and Advanced Studies of Mexico's National Polytechnic Institute, who studies trichomoniasis, a parasitic disease.

The 4 - year - old institute consists of six core research areas focused on a wide range of technologies, from cancer vaccines to robotic bees that will pollinate plants.

The ability to design new protein nanostructures could have useful implications in targeted delivery of drugs, in vaccine development and in plasmonics — manipulating electromagnetic signals to guide light diffraction for information technologies, energy production or other uses.

«This is an important demonstration of the possibilities opened up for immunotherapy by DMAb technology to direct in vivo production of antibodies of major relevance to human cancer,» said David B. Weiner, Ph.D., executive vice president of The Wistar Institute, director of The Wistar Institute Vaccine & Immunotherapy Center, W.W. Smith Charitable Trust Professor in Cancer Research, and senior author of the study.

VIP technology bypasses the requirement of the host to make its own immune response against malaria, which is what occurs with a vaccine.

The trial is sponsored by Global Health Innovative Technology Fund (Japan) and results of vaccine efficacy will be available in late 2018.

The vaccine technology clearly has a biological effect that prevents dengue,» says Derek Wallace, regional director of clinical development for Sanofi Pasteur, the French pharmaceutical firm developing the vaccine, who reported results online today at The Lancet.

Batista was one of a number of scientists involved in the study from the Ragon Institute, established in the Boston area by experts from Massachusetts General Hospital, Harvard University and the Massachusetts Institute of Technology, with the goal of working toward development of an effective vaccine against HIV / AIDS.

From that chat has arisen plans for the MSD Wellcome Trust Hilleman Laboratories — named after a vaccine scientist who worked at Merck — a non-profit research institute that it will act like a nimble biotech company with «dynamic decision - making» in the words of Ted Bianco, director of technology transfer at the Wellcome Trust.

IDMIT will contribute 1) To the development and validation of assays based on flow cytometry and mass cytometry for the evaluation of immune responses in humans and animal models; these tools will be particularly relevant for the identification of signatures of vaccine efficacy; 2) To the animal model platform, in particularly by providing access to NHP models and to new technologies for in vivo imaging infections and host responses; 3) To networking activities, in particular by organising a workshop on in vivo imaging.

These technologies are particularly powerful when looking for changes in concentrations of multiple targets under specific conditions, such as following a vaccine administration, infection, or a drug treatment.

Innovative imaging technologies to monitor responses to vaccines and infections in suitable models will provide information in characterisation of live vaccine (such as BCG) of its biodistribution and persistence.

The laboratory has also all of the technologies required to produce recombinant bacteria expressing vaccine antigens to be used as non-pathogenic vaccine vectors.

TRANSVAC will further accelerate vaccine development by developing and applying cutting - edge technologies to address critical issues in modern vaccine development and thereby increase the quality of services provided.

We share and transfer our knowledge and technologies to partners worldwide, providing opportunities for contract research and out - licensing of (in - house) developed vaccine technologies.

Today UNIL - VFL provides access to adjuvants, adjuvant quality control technology, adjuvant formulation expertise, technology transfer, training, and bespoke adjuvant R&D services, allowing partners to gain optimal benefit from the use of adjuvants and vaccine formulation technology.

Finally, the HZI will help develop in vivo imaging technologies to characterize (i) vaccine biodistribution and persistence, and (ii) cellular and molecular changes at the injection site and in draining lymphoid tissues, helping to refine the use of animal models.

iBET's infrastructure comprises 16 laboratories fully equipped with state - of - the - art technology (70 m2 each), including a BSL2 laboratory for working with viruses; a GMP Analytical Services Unit certified by the INFARMED (the Portuguese medicines authority, EMA Portuguese branch) and by DGAV (the Portuguese veterinary authority) for quality control and batch release of human and veterinary pharmaceuticals, biopharmaceuticals as well as experimental new drugs; a GMP Mass - Spectroscopy Unit that provides state - of - the - art MS services to the scientific community and Industry; a 2600 m2 bio-pilot plant supporting production and purification of proteins ATMPs and vaccines from bench top to 300 L scale and privileged access to GeniBET Biopharmaceuticals, an iBET spin - off producing ATMPs under cGMP certification for phase I / II / III clinical trials.

Through strategic partnerships with industry and nonprofit organizations, we gain access to a portfolio of priority drugs for testing within our expert focus groups, including checkpoint inhibitors, therapeutic vaccines, innate immune stimulants, targeted therapies, and many other promising treatments and technologies with high therapeutic potential.

The module «Assay Development and Validation» will provide an insight into «state of the art» applications of SPR - technology in the context of vaccine development.

We use our mammalian expression technologies to create panels of recombinant pathogen proteins that are then used to identify new subunit vaccine targets for infectious diseases.